No gym needed — my favorite trainer reveals 9 no-equipment moves to build strength anywhere
The beauty of strength training is that it doesn't have to mean pricey memberships or crowded classes. That's right, some of the most effective routines can be done at home. Thanks to my favorite trainer, Kirra Mitlo, I'm excited to share her nine-move, full-body, strength-building routine you can do anywhere.
Coach Mitlo describes the workout as 'A full-body, low-impact workout that engages all muscle groups while challenging your balance and keeping your joints happy.' There is no equipment needed, although I always suggest investing in one of the best yoga mats to increase the comfort of floor-based exercise.
If you already have an exercise mat and are ready to go, here's how the routine is structured. Kirra Mitlo recommends completing each exercise for 40 seconds, followed by 20 seconds of rest. After finishing all nine exercises, take a 60 to 90 second break, then repeat the sequence for two to three rounds.
Now, let's take a look at the moves and what Mitlo says each exercise will do for your body.
Slow Standing March + Twist
This exercise will target your obliques, hip flexors, balance, and your stability. You might feel a little bit of a "muscle burn" in the side of your stomach, and this is because we are targeting our oblique muscles which are on the outside of our abdominals (the front of your stomach).
Side Step Into a Squat + Floor Tap
This dynamic squat exercise is going to challenge your squat depth and your legs. The goal is to be able to tap the floor with your hand as you step out into the squat; however, if your knees or hips feel like they are limiting you that is okay, just reach down as far as you can comfortably.
Alternating Standing crunches
This movement is going to work on your six-pack abs, which are the front of your stomach. If you are someone who tends to get back or neck pain doing different core exercises on the floor, this standing alternating crunch is going to be a great exercise for you to practice.
Since this movement is standing, it will reduce a lot of pressure on your joints.
Side Lying Tricep Press Ups
This movement can be done lying on the floor or even lying on your bed from your side. You will have your palm flat in front of your chest, and press through that hand to lift your upper body up off the floor.
This movement targets your triceps and shoulders, it is also a great exercise to do for longevity because, as we age, it gets difficult to get up from a lying position, and having tricep strength to press your body up is going to be crucial!
Alternating Step Back + Tricep Extension
This exercise is a combination of a step back and a bodyweight tricep extension. This exercise is one of my favorites because it targets the triceps, and something about the synchronization of the step and tricep extension gives me a little serotonin boost!
Straight Arm Curl to Press
If you want to feel strong, this movement is going to be your best friend. A little pro tip is to squeeze your fists into a ball to create even more tension. This is a great way to also build muscle connection.
Air Dogs
Air dogs are a great way to improve your stability and target your glutes and shoulders. To maintain really great balance try to find one stationary spot or object in front of you to stare at, this will help you stay locked in.
Step Reverse Lunge
One of my all-time favorite lunge variations is the 2-step reverse lunge. First, you will take a small step back and dip down into a lunge, then press up and step further back into a full deep lunge. Sit as deep into these lunges as you comfortably can.
Bent Over Row + Tricep Kickback
This movement is going to target your back, glutes, upper back, and triceps! When you are completing the "row" portion of this exercise, envision a pencil between your shoulder blades on your back, and try to squeeze that "imaginary pencil". Queues like this can help build your mind-to-muscle connection so you can really feel the movement!
Whether you're just heading back to school and need a dorm-friendly routine that won't wake your neighbors, or you're someone who travels often and wants a hotel-friendly workout, or you simply want to build strength from the comfort of your own home, Mitlo's got you covered.
This no-jumping, no-equipment sequence fits into small spaces and busy schedules without any fuss.
Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
More from Tom's Guide
I cancelled my gym membership two months ago — here's how I'm staying just as fit at home
I've just tried Strava Premium — and this is the feature I'd pay for twice
I tried slow running every day for 2 weeks — and now I'm hooked
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
21 minutes ago
- CBS News
C4 mental health nonprofit struggles with late paychecks 5 years after similar crisis
Passionate mental health providers are fed up after multiple paychecks were delivered late, and they say it feels like déjà vu on top of it. CBS News Chicago has covered financial problems at the very same nonprofit before. At an all-staff meeting last week, Kerri Brown, the chief executive officer of the nonprofit Community Counseling Centers of Chicago — also known as C4 — said he knew everyone wanted to know about what was going on with payroll. "It has caused all types of anxiety, financial pain and stress to you guys," Brown told the staff. The meeting was recorded by someone whose loved one had just quit, after several weeks of emails with "difficult news" from Brown. "Temporary financial challenges," for the behavioral health provider led to late paychecks over and over. "Your job is supposed to be like the most stable thing," said a former C4 higher-up. "A dip in revenue" is how Brown initially explained the payroll problem. But the former higher-up, who asked to remain anonymous, could not stomach not knowing when her hard-earned cash would be in hand. "You kind of go into a panic," she said. "You're in shock because you're trying to think of all the things you had planned." Staffers were provided with letters to give to landlords and other bill collectors, confirming the delay in salaries for June. The problem persisted through July. In August, C4 began offering hardship assistance for rent late fees, overdraft or insufficient funds fees, utility shutoffs, and evictions or foreclosures. Another ex-employee said she had issues with her medical care, because C4 did not pay her health care premiums on time. "There's, you know, good workers there that are helping people in the community, and, you know, and no one deserves this," she said. This was not the first time C4 has run into financial issues. In 2019 and 2020, CBS News Chicago produced several stories that dug into C4's finances. Clinicians at that time also sounded the alarm on delayed paychecks. CBS News Chicago's reporting inspired the Illinois Attorney General's office to open an investigation. Five years later, the same questions are cropping up again — despite promises that the problem had been solved long before. "It was mentioned to me in an interview that I may see some reports from years ago about financial issues or struggles that the organization had, but that they were well beyond those," the former higher-up said. CEO Brown assured staff and CBS News Chicago that the nonprofit will weather the latest storm. "We're not in a place of shutdown," he told staff at the meeting. This time around, the money problems came up because unexpected flooding and broken heating and air conditioning systems decimated C4's rainy day fund. Brown said a reversal of hundreds of thousands of dollars in funding that "were certainly not our fault" also hurt. Another problem was that C4 was put on State of Illinois' "do not pay' list for about six months due to a late audit. That is now resolved, though some money still needs to be processed. The former higher-up said "at least 30 people" have resigned from C4 at this point. After a two-and-a-half-week wait for their July 25 paychecks, the therapists that remained were thanked for their "continued patience and commitment." "It's one thing to have a, you know, positive outlook in the darkness of things," said the second former employee. "It's another to ask people to buy it." Brown spoke with CBS News Chicago a few times by phone, but declined several opportunities to do an on-camera interview. He did issue this statement: "C4's story is a story of resilience, and unwavering commitment. C4's turnaround began four years ago, when C4 was losing $350-$400k per month. Despite that starting point, in the last 4 years since, this is the first occurrence of any payroll delays. In fact, C4 has been on sound financial footing. We've had three straight clean audits. We have diversified our revenue streams. C4 has significantly expanded its reach and presence in the community. We have grown in some of the most challenging times. We have repaired and restored our reputation and standing in the community by being an innovator in the industry, creating high profile, high impact therapeutic models. "Yes, we experienced tight cash flows in 2025. We had a series of large, unexpected borderline tragic events to include separate major flooding events and multiple HVAC replacements and other infrastructures issues/repairs that represented significantly large expenses. Additionally, there were unexpected obstructions of receivables and reversals of some funding channels that were not our doing and certainly not our fault. This is a mere snapshot in C4's existence; however, if you look at the entire story, you will know that this one moment does not define us! "C4 stands with Chicago's most vulnerable, delivering mental health, crisis, and substance use intervention where it is needed most. Like many nonprofits in these disruptive times, we face challenges. These hurdles are real, but they are not bigger than our mission or our determination. We continue to take decisive steps to strengthen C4 for the long haul. "We will work and overcome these temporary challenges and are grateful for our employees for their patience, commitment, and understanding."
CNN
21 minutes ago
- CNN
Cowboys owner Jerry Jones reveals decade-long battle with Stage 4 cancer diagnosis
Dallas Cowboys owner Jerry Jones credited an experimental trial drug for successfully treating advanced melanoma as he disclosed his cancer diagnosis publicly for the first time. Jones revealed his illness in a documentary series, 'America's Team: The Gambler and His Cowboys,' which will debut on Netflix next week. The 82-year-old Jones then told The Dallas Morning News how he was initially diagnosed in June 2010 and underwent two surgeries on his lung and two on his lymph nodes over the next 10 years after skin cancer cells metastasized to other parts of his body. 'Well, you don't like to think about your mortality, but I was so fortunate to have some great people that sent me in the right direction,' Jones said after practice on Wednesday. 'I got to be part of a trial that was propitious. It really worked. It's called PD-1 (therapy), and it really, really, really worked.' First-year Cowboys coach Brian Schottenheimer described Jones' fight with cancer as an 'amazing story' and praised him for going public. 'I'm glad that Jerry shared it, just because I think it gives people hope,' Schottenheimer said Wednesday. 'It gives people the strength to say … 'Hey, you can beat this.'' Schottenheimer, 51, used his last news conference of the Cowboys' nearly monthlong stay in Southern California to talk about his own cancer diagnosis. He underwent surgery in 2003 for thyroid cancer at the Mayo Clinic in Rochester, Minnesota. Then-Washington Commanders owner Dan Snyder helped arrange Schottenheimer's treatment two years after firing his father, Marty Schottenheimer, as coach. Brian Schottenheimer was Washington's quarterbacks coach during the 2001 season, the same year Snyder himself was treated for thyroid cancer. 'It doesn't discriminate against anybody,' Schottenheimer said. 'And mine was certainly less serious, but I was 28 when I was diagnosed with thyroid cancer. Nothing like Stage 4, nothing like what Jerry and other people have to go through. But you hear that word 'cancer,' and it scares the hell out of you.'
Yahoo
23 minutes ago
- Yahoo
HeartBeam Reports Second Quarter 2025 Results
Executing on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the 510(k) Application Increased Business Development Resources to Match Inbound Interest from Industry Partners Management to Host Webcast and Conference Call Today at 4:30 p.m. ET SANTA CLARA, Calif., August 13, 2025--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter & Subsequent 2025 Operational Highlights The Company continues to make significant progress towards commercial readiness, along with key clinical and regulatory achievements on the HeartBeam System. 12-Lead ECG Synthesis Software FDA Submission: Productive discussions are ongoing with FDA on 510(k) submission for the 12-lead ECG synthesis software in arrhythmia assessment. Timeline for FDA clearance remains firmly on track, expected by the end of the year. Presented results from pivotal VALID-ECG study in April, demonstrating that HeartBeam successfully met the clinical endpoints, with a 93.4% overall diagnostic agreement indicating that the synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs. Commercial Readiness Plans: Anticipate initiating commercialization upon receiving 510(k) clearance for the 12-lead ECG synthesis software. Executing on commercial readiness plans, including finalizing cardiology reader service to provide on-demand cardiologist reviews of synthesized 12-lead ECGs and triage patients. Established infrastructure for customer service, contract manufacturing, and logistics and fulfillment efforts. Proximity to FDA Clearance and commercialization is intensifying business development activity. Expanded the business development team with recognized industry expert. Other Highlights: Abstract on HeartBeam AI algorithm accepted for presentation at HRX Live 2025 in September. New international patent issued, increasing the Company's moat around its core technology; total of 21 issued patents worldwide. Received two additional industry recognitions, adding to the growing list of recent industry recognitions: Awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards for its groundbreaking ECG technology. Named finalist in 2025 Octane High Tech Awards, which recognizes innovators, entrepreneurs and technology leaders with a presence in Orange County. Cash, cash equivalents, and short-term investments totaled $5.1 million as of June 30, 2025, with net cash used in operating activities of $3.4 million for the three months ended June 30, 2025, resulting in a 23% decrease quarter-over-quarter. Management Commentary "In the quarter, we continued to engage in positive and productive discussions with the FDA on the 12-lead ECG synthesis software submission for arrhythmia assessment and we continue to anticipate clearance by the end of the year. As we have discussed, that clearance, together with our foundational clearance, will form the basis for our commercial launch," said Robert Eno, Chief Executive Officer, HeartBeam. "We continue to make significant progress with commercial readiness plans, which is positioning us for a successful launch following 510(k) clearance of our 12-lead synthesis software. "Additionally, we are seeing a marked increase in interest from industry partners as we get closer to our 12-lead ECG synthesis clearance and commercialization. We believe these players understand that HeartBeam's technology is transformative and is an ideal platform in the form of a cable free ECG that produces a synthesized 12-lead ECG output. There are multiple ways for partners to get involved in the HeartBeam ecosystem, including data and AI, companion products and services, and complementary diagnostics and treatments. "Our vision for the near future is to bring additional capabilities of a synthesized 12-lead ECG into patients' hands outside of the healthcare setting. One of the most important trends in medicine today is the movement of medical grade devices from the hospital and clinic to the patient. Accurate, connected, medical grade technologies have been shown to expand access, reduce healthcare costs and enable personalized medicine. Within cardiac diseases there is a major gap and a huge opportunity. Cardiac diseases are the leading cause of death worldwide and most cardiac events, whether arrhythmias or ischemia, happen outside of the healthcare setting. Diagnosing these events is crucial for patients and for the healthcare system and we believe that as we implement our vision, our technology will be well positioned to accomplish this," concluded Eno. Second Quarter 2025 Financial Results Research and development expenses for the second quarter of 2025 were $3.3 million, compared to $2.8 million for the second quarter of 2024. General and administrative expenses for the second quarter of 2025 were $1.7 million compared to $2.2 million for the second quarter of 2024. Net loss for the second quarter of 2025 was $5.0 million, compared to a net loss of $5.0 million for the second quarter of 2024. Net cash used in operating activities was $7.9 million for the six months ended June 30, 2025, as compared to $7.0 million for the six months ended June 30, 2024. Cash, cash equivalents, and short-term investments totaled $5.1 million as of June 30, 2025, with net cash used in operating activities of $3.4 million during the period. Second Quarter 2025 Results Conference Call HeartBeam CEO Robert Eno and CFO Tim Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. To access the call, please use the following information: Date: Wednesday, August 13, 2025 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Dial-in: 1-844-826-3035 International Dial-in: 1-412-317-5195 Conference Code: 10201583 Webcast: HeartBeam Second Quarter 2025 Earnings Conference Call A telephone replay will be available approximately three hours after the call and will run through November 13, 2025, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 10201583. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company's investor relations section here. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement. For additional information, visit Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Cleared Indications for Use The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual. HEARTBEAM, INC. Condensed Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2025 December 31, 2024 Assets Current Assets: Cash and cash equivalents $ 3,256 $ 2,377 Short-term investments (Note 3) 1,797 — Prepaid expenses and other current assets 308 393 Total Current Assets 5,361 2,770 Property and equipment, net 564 450 Other assets 56 56 Total Assets $ 5,981 $ 3,276 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable (includes related party $0 and $5, respectively) $ 814 $ 531 Accrued expenses (includes related party $5 and $0, respectively) 985 1,091 Total Current Liabilities 1,799 1,622 Total Liabilities 1,799 1,622 Commitments (Note 7) Stockholders' Equity Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June 30, 2025 and December 31, 2024 — Common stock - $0.0001 par value 100,000,000 shares authorized; 34,020,340 and 26,960,901 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4 3 Additional paid in capital 70,909 57,924 Accumulated deficit (66,731 ) (56,273 ) Total Stockholders' Equity 4,182 1,654 Total Liabilities and Stockholders' Equity $ 5,981 $ 3,276 HEARTBEAM, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Operating Expenses: General and administrative $ 1,711 $ 2,246 $ 3,720 $ 4,602 Research and development 3,326 2,844 6,818 5,272 Total operating expenses 5,037 5,090 10,538 9,874 Loss from operations (5,037 ) (5,090 ) (10,538 ) (9,874 ) Other Income and (Expense) Interest income 63 134 80 312 Total other income 63 134 80 312 Loss before provision for income taxes (4,974 ) (4,956 ) (10,458 ) (9,562 ) Income tax provision — — — — Net Loss $ (4,974 ) $ (4,956 ) $ (10,458 ) $ (9,562 ) Net loss per share, basic and diluted $ (0.15 ) $ (0.19 ) $ (0.32 ) $ (0.36 ) Weighted average common shares outstanding, basic and diluted 33,834,950 26,566,832 32,184,025 26,538,863 HEARTBEAM, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) Six months ended June 30, 2025 2024 Cash Flows From Operating Activities Net loss $ (10,458 ) $ (9,562 ) Adjustments to reconcile net loss to net cash used in operating activities Depreciation 15 — Stock based compensation expense 2,286 2,247 Changes in operating assets and liabilities: Prepaid expenses and other current assets 85 92 Accounts payable and accrued expenses 150 210 Net cash used in operating activities (7,922 ) (7,013 ) Cash Flows From Investing Activities Purchase of property and equipment (102 ) (98 ) Purchase of short-term investments (3,760 ) — Maturities of short-term investments 1,963 — Net cash used in investing activities (1,899 ) (98 ) Cash Flows From Financing Activities Proceeds from sale of equity, net of issuance costs 10,250 — Proceeds from sale of equity under ATM, net of issuance costs 450 76 Proceeds from exercise of stock options — 8 Net cash provided by financing activities 10,700 84 Net increase (decrease) in cash and restricted cash 879 (7,027 ) Cash, cash equivalents and restricted cash – Beginning of period 2,433 16,239 Cash, cash equivalents and restricted cash – Ending of period $ 3,312 $ 9,212 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,256 $ 9,157 Restricted cash (included in other assets) 56 55 Total cash, cash equivalents and restricted cash $ 3,312 $ 9,212 Supplemental Disclosures of Cash Flow Information: Purchase of property and equipment in accounts payable $ 27 $ 16 Taxes paid $ — $ — View source version on Contacts Investor Relations Contact: Chris Tyson Executive Vice PresidentMZ North AmericaDirect: 949-491-8235BEAT@ Media Contact: media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
